Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - August 2022 Vol 12, No 4

Editorial

Case Reports

Original Article

Practical Issues in Pharmacy Management

FDA Oncology Update

ASCO Highlights

Editorial

Optimal Sequencing of Cancer Treatments an Increasingly Important Question

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Case Reports

Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer

Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD

Original Article

Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer

Nicholas J. Newman, PharmD; Sara E. Gordon, PharmD, BCOP; Charles J. Nock, MD; Christopher J. Burant, PhD; Candice M. Wenzell, PharmD, BCOP

The Link Between Hypoalbuminemia and Oral Tyrosine Kinase Inhibitor Adverse Events in Adults with Malignant Solid Tumors

Jessica Marini, PharmD, BCOP; Bailey Bass Hammond, PharmD; Jacob Rennebaum, PharmD; Erin Weeda, PharmD, BCPS; Jagoda Misniakiewicz, PharmD; Amy Sion, PharmD, BCOP

Safety and Efficacy of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients with Cancer and Baseline Renal Dysfunction

Emily H. Hsu, PharmD, and Ryan Beechinor, PharmD, BCPS, BCOP

Practical Issues in Pharmacy Management

Sterility of Single-Use Vials When Using a Closed-System Transfer Device

Joan Antoni Schoenenberger-Arnaiz, PharmD, PhD; Maria Nevot-Blanc, PharmD; Merce Garcia-Gonzalez, PharmD; Mireia Martinez-Sogues, PharmD; Aida Moroba-Estor; Laura Rumi-Carrera, PharmD; Jason Battle, BS

FDA Oncology Update

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma

Tafinlar plus Mekinist First Tumor Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

Online Only

FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality

Online Only

Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma